Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Limb Girdle Muscular Dystrophy Market Segmentation
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary
2.Global Limb Girdle Muscular Dystrophy (LGMD) Market Introduction
2.1.Global Limb Girdle Muscular Dystrophy (LGMD) Market - Taxonomy
2.2.Global Limb Girdle Muscular Dystrophy (LGMD) Market - Definitions
2.2.1.By Type
2.2.2.By Treatment
2.2.3.By Region
3.Global Limb Girdle Muscular Dystrophy (LGMD) Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
4.Global Limb Girdle Muscular Dystrophy (LGMD) Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Limb Girdle Muscular Dystrophy (LGMD) Market By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Limb-Girdle Muscular Dystrophy Type A (Dominant)
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Limb-Girdle Muscular Dystrophy Type B (Recessive)
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6.Global Limb Girdle Muscular Dystrophy (LGMD) Market By Treatment, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Corticosteroids
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Gene Therapy
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Stem Cell Therapy
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7.Global Limb Girdle Muscular Dystrophy (LGMD) Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8.North America Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
8.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
8.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1.Corticosteroids
8.2.2.Gene Therapy
8.2.3.Stem Cell Therapy
8.2.4.Others
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
9.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
9.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Corticosteroids
9.2.2.Gene Therapy
9.2.3.Stem Cell Therapy
9.2.4.Others
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
10.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
10.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Corticosteroids
10.2.2.Gene Therapy
10.2.3.Stem Cell Therapy
10.2.4.Others
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Latin America Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
11.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
11.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Corticosteroids
11.2.2.Gene Therapy
11.2.3.Stem Cell Therapy
11.2.4.Others
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Brazil
11.3.2.Mexico
11.3.3.Rest of LA
12.Middle East and Africa Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
12.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
12.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Corticosteroids
12.2.2.Gene Therapy
12.2.3.Stem Cell Therapy
12.2.4.Others
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.GCC Countries
12.3.2.South Africa
12.3.3.Rest of MEA
13. Global Limb Girdle Muscular Dystrophy (LGMD) Pipeline Assessment - Pipeline Drug Analysis
13.1. Limb Girdle Muscular Dystrophy (LGMD) -Pipeline Assessment, by Region
13.2. Limb Girdle Muscular Dystrophy (LGMD) -Pipeline Drugs Assessment - by Sponsors/Companies
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.BridgeBio Pharma Inc.
14.2.2.Jubilant Cadista Pharmaceuticals Inc.
14.2.3.Aden Pharmaceuticals Private Limited
14.2.4.ML Bio Solutions Inc.
14.2.5.Genethon
14.2.6.Sarepta Therapeutics Inc.
14.2.7.Asklepios Biopharmaceutical Inc.
14.2.8.Atamyo Therapeutics
14.2.9.Simone Spuler MD
15. Research Methodology
16. Appendix and Abbreviations
2.Global Limb Girdle Muscular Dystrophy (LGMD) Market Introduction
2.1.Global Limb Girdle Muscular Dystrophy (LGMD) Market - Taxonomy
2.2.Global Limb Girdle Muscular Dystrophy (LGMD) Market - Definitions
2.2.1.By Type
2.2.2.By Treatment
2.2.3.By Region
3.Global Limb Girdle Muscular Dystrophy (LGMD) Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
4.Global Limb Girdle Muscular Dystrophy (LGMD) Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Limb Girdle Muscular Dystrophy (LGMD) Market By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Limb-Girdle Muscular Dystrophy Type A (Dominant)
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Limb-Girdle Muscular Dystrophy Type B (Recessive)
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6.Global Limb Girdle Muscular Dystrophy (LGMD) Market By Treatment, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Corticosteroids
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Gene Therapy
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Stem Cell Therapy
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7.Global Limb Girdle Muscular Dystrophy (LGMD) Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8.North America Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
8.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
8.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1.Corticosteroids
8.2.2.Gene Therapy
8.2.3.Stem Cell Therapy
8.2.4.Others
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
9.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
9.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Corticosteroids
9.2.2.Gene Therapy
9.2.3.Stem Cell Therapy
9.2.4.Others
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
10.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
10.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Corticosteroids
10.2.2.Gene Therapy
10.2.3.Stem Cell Therapy
10.2.4.Others
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Latin America Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
11.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
11.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Corticosteroids
11.2.2.Gene Therapy
11.2.3.Stem Cell Therapy
11.2.4.Others
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Brazil
11.3.2.Mexico
11.3.3.Rest of LA
12.Middle East and Africa Limb Girdle Muscular Dystrophy (LGMD) Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Limb-Girdle Muscular Dystrophy Type A (Dominant)
12.1.2.Limb-Girdle Muscular Dystrophy Type B (Recessive)
12.2. Treatment Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Corticosteroids
12.2.2.Gene Therapy
12.2.3.Stem Cell Therapy
12.2.4.Others
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.GCC Countries
12.3.2.South Africa
12.3.3.Rest of MEA
13. Global Limb Girdle Muscular Dystrophy (LGMD) Pipeline Assessment - Pipeline Drug Analysis
13.1. Limb Girdle Muscular Dystrophy (LGMD) -Pipeline Assessment, by Region
13.2. Limb Girdle Muscular Dystrophy (LGMD) -Pipeline Drugs Assessment - by Sponsors/Companies
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.BridgeBio Pharma Inc.
14.2.2.Jubilant Cadista Pharmaceuticals Inc.
14.2.3.Aden Pharmaceuticals Private Limited
14.2.4.ML Bio Solutions Inc.
14.2.5.Genethon
14.2.6.Sarepta Therapeutics Inc.
14.2.7.Asklepios Biopharmaceutical Inc.
14.2.8.Atamyo Therapeutics
14.2.9.Simone Spuler MD
15. Research Methodology
16. Appendix and Abbreviations
BridgeBio Pharma Inc.
Jubilant Cadista Pharmaceuticals Inc.
Aden Pharmaceuticals Private Limited
ML Bio Solutions Inc.
Genethon
Sarepta Therapeutics Inc.
Asklepios Biopharmaceutical Inc.
Atamyo Therapeutics
Simone Spuler MD
Jubilant Cadista Pharmaceuticals Inc.
Aden Pharmaceuticals Private Limited
ML Bio Solutions Inc.
Genethon
Sarepta Therapeutics Inc.
Asklepios Biopharmaceutical Inc.
Atamyo Therapeutics
Simone Spuler MD